home / stock / pdsb / pdsb news

PDSB News and Press, PDS Biotechnology Corporation From 11/08/21

Stock Information
Company Name: PDS Biotechnology Corporation
Stock Symbol: PDSB
Market: NASDAQ
Website: pdsbiotech.com
Menu
PDSB PDSB Quote PDSB Short PDSB News PDSB Articles PDSB Message Board
Get PDSB Alerts

News, Short Squeeze, Breakout and More Instantly...
PDSB - PDS Biotechnology inks licensing agreement with National Cancer Institute

PDS Biotechnology (NASDAQ:PDSB) announces a licensing agreement with the National Cancer Institute (NCI) for intellectual property related to the NCI’s proprietary tumor-associated and immunologically active T-cell receptor gamma alternate reading frame protein (TARP). The worldwide, n...
PDSB - PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute

Advances Next Phase of Versamune ® Oncology Pipeline FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versam...

PDSB - PDS Biotech to license antigens from University of Georgia for universal flu vaccine

PDS Biotechnology (NASDAQ:PDSB) has licensed COBRA (Computationally Optimized Broadly Reactive Antigen) antigens from the University of Georgia for use in the development of PDS0202, its universal flu vaccine candidate. The antigens were selected following pre-clinical development work c...

PDSB - PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Universal Flu Vaccine

FLORHAM PARK, N.J., Nov. 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating techn...
PDSB - PDS Biotech Chief Medical Officer, Lauren V. Wood, to Present at the 2021 International Head and Neck Cancer Conference

FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating techn...

PDSB - PDS Biotechnology Corp (PDSB) - Phase 2 Treatment Continues As New Patient Recruitment Is Delayed

Friday, October 22, 2021 PDS Biotechnology Corp (PDSB) Phase 2 Treatment Continues As New Patient Recruitment Is Delayed PDS Biotechnology Corp operates as a clinica Read More >>

PDSB - PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating techn...
PDSB - PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination

FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced the tempo...

PDSB - PDS Biotechnology Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results

FLORHAM PARK, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, will release financial re...

PDSB - PDS Biotechnology Welcomes Matthew Hill as Chief Financial Officer

FLORHAM PARK, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Matthew H...
Previous 10 Next 10